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Introduction
The prognostic significance of CD20 expression has been
investigated in B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) but is still a subject of debate. In childhood ALL,
Borowitz et al.1 found that high CD20 intensity correlated with
poorer event-free survival, while Jeha et al.2 did not recognize
CD20 as an adverse prognostic factor. The first study in adults
was carried out by Thomas et al.3 CD20 positivity (20% or over
positive ALL cells) was associated with worse disease-free sur-
vival (DFS) and overall survival (OS), an effect especially rele-
vant in patients under 30 years of age. This adverse prognostic
impact was confirmed by the French group4 but only in
patients with a white blood cell (WBC) count over 30¥109/L.
Another recent report failed to document such prognostic rele-
vance in unselected patients and in discrete subsets identified
by WBC count and genetics.5 The aim of our study was to cor-
relate CD20 expression with clinical-biological characteristics
and outcome in Philadelphia-negative (Ph-) BCP-ALL patients
prospectively treated within the multicenter NILG 09-2000
study,6 designed to direct post-remission strategy from mini-
mal residual disease (MRD) assessment. There is currently no
information available on MRD response according to CD20
antigen expression which could shed light on the real clinical
impact of this B-lineage differentiation molecule in adult ALL.
Design and Methods
Study design
The NILG 09-2000 prospective program was based on MRD results,
assessed by real-time quantitative polymerase chain reaction (RQ-
PCR). The study was approved by the institutional review board and
patients were enrolled after giving their written informed consent in
accordance with the Declaration of Helsinki. Quantitative evaluation
of chimeric transcript was exploited for BCP-ALL cases harboring
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The prognostic significance of CD20 expression in acute
lymphoblastic leukemia has been investigated in children
and adults but is still a subject of debate. The aim of our
study was to correlate CD20 expression with clinical-biolog-
ical characteristics and outcome in 172 Philadelphia-negative
patients prospectively treated in a multicenter trial introduc-
ing the molecular evaluation of minimal residual disease for
therapeutic purposes. We considered 20% as the threshold
for CD20 positivity. Complete remission rate, minimal resid-
ual disease negativity rate at weeks 10, 16 and 22, and dis-
ease-free and overall survival were similar among CD20 pos-
itive and negative patients, even considering minimal resid-
ual disease results and related therapeutic choices. Our study
failed to demonstrate any prognostic significance for CD20
expression in Philadelphia-negative acute lymphoblastic
leukemia. This conclusion is supported for the first time by a
comparable minimal residual disease response rate among
CD20 negative and positive patients. ClinicalTrials.gov ID,
NCT00358072
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BRIEF REPORTS
fusion genes. In all the other cases, leukemia-specific probes were
generated by genomic amplification and sequencing of the VDJ/VJ
regions of immunoglobulin heavy chain (IgH) or the kappa light
chain (IgK). The treatment plan had 2 distinct phases. The first
phase was applicable to all patients, allowing the MRD response
to be defined. For MRD assessment, 3 serial bone marrow (BM)
samples were prospectively withdrawn before cycles 4, 6, and 8,
corresponding to the ends of treatment weeks 10 (MRD-1), 16
(MRD-2), and 22 (MRD-3). The critical points for assigning an
MRD risk classification coincided with MRD-2 and MRD-3. Only
patients bearing t(4;11) translocation could proceed straight to allo-
geneic stem cell transplantation (SCT). In all other patients, the sec-
ond phase depended on MRD status, with maintenance therapy
prescribed to MRD-negative (MRD-neg) patients, and
sibling/unrelated allogeneic SCT or multiple “hypercycles” sup-
ported by autologous stem cells to MRD-positive (MRD-pos)
patients. MRD negativity was defined by a RQ-PCR assay less
than 10-4 at MRD-2 and completely negative at MRD-3. Patients
without molecular probe were treated according to clinical risk.
Patients with Ph+ ALL received a modified treatment7 and were
excluded from this analysis.
Immunophenotyping
Immunophenotyping was performed according to the recom-
mendations from the European Group for the Immunological char-
acterization of Leukemias8 in multiparameter flow cytometry with
CD45 gating9. Phenotypic data were expressed as the percentage
of CD20 positive cells on the whole leukemic population. The
phenotypic analysis was performed on bone marrow and periph-
eral blood in 146 and 26 patients, respectively. We considered 20%
as the threshold for positivity (CD20-pos).
Statistics
The probabilities of favorable outcome (CR, MRD negativity)
were compared using the χ2 test with Yates correction. DFS and
survival curves were plotted using the Kaplan-Meier method and
compared by the log rank test. Multivariate analyses were carried
out by Cox’s linear regression model, including all variables
expressing significant P values in univariate analysis. P<0.05 was
considered significant.
Results and Discussion
Between March 2000 and September 2008, 403 consecu-
tive ALL patients were enrolled in the study, including 172
patients with Ph-negative BCP-ALL (Table 1). Fifty-two
(30.2%) patients resulted CD20-positive. Median value of
CD20 expression within CD20-positive patients was 67%
(range 25-100%). As expected, the distribution of EGIL clas-
sification was correlated to CD20 status: the B-I phenotype
(pro-B CD10-) was more frequent in the CD20-negative
group (38.4%) than in the CD20-positive group (7.6%;
P<0.0001). On the contrary, B-II phenotype was more fre-
quently associated with CD20 positivity (77.0%) than neg-
ativity (45.8%; P<0.0001). A prevalence of hepato-
splenomegaly was also noted in CD20-positive patients. As
regards outcome, overall CR rate was 84.3% (n=145), with
no difference seen between the two groups (43 CD20-neg-
ative 82.7%; 102 CD20-positive 85%). Since treatment was
MRD-oriented, it was possible to look for correlations
between CD20 expression and MRD course. One or more
sensitive (≥10-4) patient-specific molecular probes were
available for 124 of 172 (72.1%) study patients (Figure 1). A
non-significant trend for more markers being available was
noted in the CD20-negative subset, despite the fact that 29
patients with highly specific single fusion gene as molecu-
lar marker belonged to this group (25 with t[4;11] and 4
with t[1;19]). The association between t(4;11) and CD20
negativity accounted for fewer MRD data available in this
group, due to early treatment failure or shift to allogeneic
SCT. The rate of MRD negativity achieved at the three time
points was similar for CD20-positive and CD20-negative
patients (Figure 1) and CD20 expression had no impact on
DFS and OS in the entire patient cohort (Figure 2A and B),
nor did it affect outcome of specific subgroups defined by
patient age, WBC count, EGIL immunophenotype and
cytogenetics/genetics (Online Supplementary Appendix). The
exclusion of t(4;11)+ ALL from analysis did not alter this
result, and no difference was documented varying CD20
positivity threshold from 20% to 10 and 30%, respectively.
Focusing on the decisional time points for final treatment
allocation (MRD-2 and MRD-3), we investigated the signif-
icance of CD20 within MRD-defined groups receiving
either maintenance because MRD-negative or transplanta-
tion-based therapy because MRD-positive. Eighty-nine of
145 CR patients (61.4%) could be classified according to
MRD study results. This group included 86 patients assess-
able at MRD-2 and MRD-3 time points as per protocol
design (Figure 1), plus 3 further patients without MRD-3
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Table 1. Patients’ characteristics.
Overall (172) CD20+ (52) CD20- (120) P value
Age, median (range) 37 (16-68) 41 (16-68) 37 (16-65) ns
WBC ¥109/L, median (range) 10.0 (0.5-730) 7.9 (0.5-330) 11.5 (1-730) ns
LDH U/L, median 851 815 922 ns
PB blasts %, median (range) 56 (0-100) 53 (0-100) 60 (0-100) ns
Splenomegaly, n (%) 70 (40.7%) 28 (53.8%) 42 (35.0%) 0.067
Hepatomegaly, n (%) 55 (32.0%) 24 (46.2%) 31 (25.8%) 0.014
EGIL B-I, n (%) 50 (29.1%) 4 (7.6%) 46 (38.4%) <0.0001
EGIL B-II, n (%) 96 (55.8%) 40 (77.0%) 55 (45.8%) <0.0001
EGIL B-III, n (%) 26 (15.1%) 8 (15.4%) 19 (15.8%) ns
Cytogenetics, unfavorable 51 (29.7%) 11 (21.2%) 40 (33.3%) ns
t(4;11)/MLL 25 (14.6%) 0 25 (20.8%) N/A
other* 26 (15.1%) 11 (21.2%) 15 (12.5%) ns
Cytogenetics, standard 121 (70.3%) 41 (78.8%) 80 (66.6%) ns
*Other : del(6q) (n=2), -7 (n=2), +8 (n=7), low hypodiploidy (30-39 chromosomes) (n=5), near triploidy (60-78 chromosomes) (n=7), complex with ≥ 5 abnormalities (n=3). ns:
non-significant P value; N/A: not applicable.
analysis but heavily positive at MRD-2 (MRD-positive,
n=2) or totally negative at MRD-1 and MRD-2 (MRD-neg-
ative, n=1). The remaining CR patients were excluded from
MRD analysis because of early removal (relapse, toxicity,
transfer to SCT) or because they lacked a molecular probe.
Five-year survival rates were similar among CD20-positive
F. Mannelli et al.
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Figure 2. (A) Overall survival and (B) disease-free survival according to CD20 status in the whole cohort. Overall survival according to CD20
status in patients resulting MRD-neg (C) and MRD-pos (D), by treatment intention. Overall survival according to CD20 status in patients
resulting MRD-neg and treated with maintenance (C) or MRD-pos and receiving allogeneic SCT or high-dose therapy with autotransplanta-
tion (D). Follow-up intervals in months.
Figure 1. Outline of
protocol NILG-ALL
09/00, MRD study,
and treatment flow in
the whole cohort and
according to CD20
expression. MRD-neg
rate: minimal resid-
ual disease negativity
rate; SCT: stem cell
transplantation; rel:
relapse; MRD
probe(s) refers to the
availability of a clon-
ality marker.
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and CD20-negative subsets in patient populations classified
as MRD-negative or -positive, respectively (Figure 2C and
D), according to intention to treat. With regards to actual
treatment, 49 of 51 MRD-neg patients received mainte-
nance, with a superimposable outcome between CD20-
positive (n=16) and CD20-negative (n=33) cases (Figure 2E);
and 27 of 38 MRD-positive patients received allogeneic
SCT (n=14, 10 CD20-negative and 4 CD20-positive) or
high-dose treatment with autologous rescue (n=13, 9
CD20-negative and 4 CD20-positive), once again without
any prognostic influence related to CD20 expression (Figure
2F).
In conclusion, our study failed to demonstrate a prognos-
tic significance for CD20 expression in BCP-ALL. While the
discrepancy between our data and that of others might be
related to differences in study design and therapeutic strat-
egy, the study confirmed the leading prognostic relevance
of MRD response in Ph- BCP-ALL, the rate of molecular CR
being the same among CD20-positive and CD20-negative
patients (60%), with an excellent survival plateau of over
70% at 5-8 years in both CD20-negative/MRD-negative
and CD20-positive/MRD-negative patients treated with
chemotherapy only. These findings are consistent with the
results of another large trial investigating the significance of
phenotype in BCP-ALL, in which no prognostic role was
documented for the EGIL B-I subgroup (pro-B), that is most
often CD20-negative10. An exception to that is represented
in our study by t(4;11)+ ALL, that is consistently CD20-neg-
ative and is a well known very high-risk subset, with high
propensity for relapse and clear indications for allogeneic
SCT. Therefore, it could still be possible that a high inci-
dence of CD20-negative t(4;11)+ ALL in unselected series
like ours (14.5%) could in part compensate the potential
worsening effect of CD20-positive cases reported in series
with lower incidence of t(4;11)+ ALL. However, even
excluding the highly adverse cytogenetic subset of t(4;11)+
ALL which is typically CD20-negative, CD20 was not prog-
nostically relevant in the context of the MRD-based prog-
nostic analysis.
We showed for the first time how the molecular response
to early chemotherapy at three distinct time points
between weeks 10 and 22 and the related clinical outcome
were similar among CD20-positive and CD20–negative
patient subsets. Because MRD was the main predictor for
relapse in multivariate analysis6, this finding alone, obtained
in a relatively large series of 89 patients evaluable for MRD
and studied prospectively, argues against the independent
prognostic value of CD20 expression in adult ALL, and doc-
uments how the analysis of CD20 clinical significance
requires a concurrent MRD evaluation. As regards treat-
ment, our data supports the view that allogeneic SCT may
not be necessary as first-line therapy in CD20-
positive/MRD-negative patients, although it remains an
effective treatment modality for CD20-positive ALL.11
Instead, transplantation results were rather poor in CD20-
positive/MRD-positive patients. Since the CD20 and CD19
antigens (the latter being broadly expressed in B-lineage
ALL) are useful therapeutic targets in CD20+ ALL, as recent-
ly reported by Thomas et al.12 and Topp et al.,13 an additive
therapeutic effect from rituximab and/or blinatumomab
should be primarily assessed in patients with MRD-posi-
tive/CD20-positive ALL before an allogeneic SCT.
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